Traders should monitor June 2026 for topline data readout, which will be the key catalyst for stock movement. A positive outcome could position OCS-01 as the first topical DME therapy, opening a major new market segment and potentially revaluing the company significantly.
Price Chart
Executive Summary
Oculis announced completion of the final patient visit in its Phase 3 DIAMOND program for OCS-01, a topical eye drop treatment for diabetic macular edema (DME), with topline results expected in June 2026. This marks a key milestone toward a potential first-in-class non-invasive therapy for DME, a condition affecting millions and often undertreated due to the burden of current invasive options.
Key Facts
- Final patient visit completed in the Phase 3 DIAMOND program for OCS-01 in DME, with topline results expected in June 2026.
- OCS-01 is a non-invasive, topical eye drop leveraging OPTIREACH® technology to deliver dexamethasone to the retina.
- Over 800 patients were enrolled across two double-masked, randomized trials (DIAMOND-1 and DIAMOND-2) with primary endpoint at 52 weeks.
- Potential NDA submission planned for Q4 2026 if results are positive.
- An estimated 1 million of 1.8 million DME patients in the U.S. are untreated or underserved, representing a $3B market opportunity.
Financial Impact
Potential blockbuster opportunity if approved — addresses $3B U.S. market with high unmet need; no financial results or revenue impact yet as trial is ongoing.
Risk Factors
- Phase 3 results may not replicate earlier positive signals from Stage 1 of the DIAMOND program.
- Regulatory approval is not guaranteed even with positive data; NDA submission depends on outcome.
- Competition from existing and emerging DME therapies could limit adoption even if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276737 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $7.83 (−10.62%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $7.83 (−28.82%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $7.83 (−28.69%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $7.83 (+65.51%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $7.83 (−74.82%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $7.83 (−71.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers